RecruitingNCT04411043
Observatory of Prolymphocytic Leukemia T
Studying T-cell prolymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- French Innovative Leukemia Organisation
- Principal Investigator
- Kamel LARIBI, DrFrench Innovative Leukemia Organisation
- Intervention
- Molecular caracterization(behavioral)
- Enrollment
- 50 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (1)
- Chd Le Mans, Le Mans, France
Collaborators
University Hospital, Lille
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04411043 on ClinicalTrials.govOther trials for T-cell prolymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06810778Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Jonsson Comprehensive Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT04629729FT819 in Subjects With B-cell MalignanciesFate Therapeutics
- ACTIVE NOT RECRUITINGPHASE1NCT04684563huCART19-IL18 in CD19+ CancersUniversity of Pennsylvania
- ACTIVE NOT RECRUITINGPHASE1NCT04732845Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid MalignanciesBenjamin Tomlinson
- ACTIVE NOT RECRUITINGPHASE1NCT00586391CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLLBaylor College of Medicine